Status:
COMPLETED
Cost-effectiveness of Nursing Interventions for Patients With PD
Lead Sponsor:
Radboud University Medical Center
Collaborating Sponsors:
ZonMw: The Netherlands Organisation for Health Research and Development
Zambon SpA
Conditions:
Parkinson Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Background: Current guidelines recommend that every person with Parkinson's disease (PD) should have access to Parkinson's Disease Nurse Specialist (PDNS) care. Thus, hospitals increasingly offer PDNS...
Detailed Description
1. Background The Parkinson's Disease Nurse Specialist (PDNS) can fulfill a pivotal role in the multidisciplinary team of people with PD. The PDNS was introduced in 1989 in the United Kingdom to bridg...
Eligibility Criteria
Inclusion
- A diagnosis of idiopathic PD;
- Sufficient knowledge of the Dutch language to fill out questionnaires;
- Age 18 years or older at the time of diagnosis;
- All disease stages, regardless of disease severity or disease duration;
- Not having received care from a PDNS in the past two years;
- A score of ≥ 18 on the Mini-Mental State Examination (MMSE13) and ≥ 12 on the Frontal Assessment Battery (FAB14).
Exclusion
- A type of atypical parkinsonism caused by medication (e.g. neuroleptics), a metabolic disorder (e.g. Wilson's disease), encephalitis or a neurodegenerative disorder (e.g. multiple system atrophy, progressive supranuclear palsy, corticobasal syndrome).
- Residing in a nursing home or another type of residential care facility (because the PDNS is not operational there).
- Any other medical or psychiatric disorder that, in the opinion of the researcher, may compromise participation in the study.
Key Trial Info
Start Date :
January 7 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 30 2023
Estimated Enrollment :
242 Patients enrolled
Trial Details
Trial ID
NCT03830190
Start Date
January 7 2019
End Date
October 30 2023
Last Update
November 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Radboud University Medical Center, Department of Neurology
Nijmegen, Gelderland, Netherlands, 6525 GC